Ashfield Engage, part of UDG Healthcare plc, today announced that it has been selected by U.S.-based Pacira BioSciences Inc. to provide strategic commercialization services for the company’s non-opioid pain management products in select European countries. Pacira has partnered with Ashfield Engage to develop a commercial strategy and deliver outsourced operations in numerous European countries, including the UK, Germany, Sweden, Austria, the Netherlands and Finland.
The U.S. Federal Trade Commission filed a lawsuit against Endo Pharmaceuticals and Impax Laboratories that alleges a 2017 agreement eliminated competition between the companies for the pain medicine oxymorphone ER.
Addressing Spikes in Substance Use Disorder Following COVID-19 Date: Wednesday, September 23, 2020 Time: 01:00 – 02:00 PM EDT Duration: 1 Hour Register Here As communities worry about a second spike in COVID-19, many are overlooking the current spike in substance use disorder (SUD). Prolonged social isolation, heightened anxiety and depression, and a […]
Mallinckrodt announced a $1.6 billion opioid settlement that will put the company’s generics business into bankruptcy.
A print advertisement of Alkermes Plc’s addiction treatment Vivitrol is false or misleading as the ad omits important risk information associated with the drug’s use, the Food and Drug Administration said in a warning letter to the company.
Dublin, Ireland-based Alkermes is acquiring Boston-based Rodin Therapeutics for $100 million up front and up to $850 million in milestone payments.
For Halloween, BioSpace collected six tales of thrills and chills from the pharma and biotech industries that will surely have you covering your eyes in terror.
Baxter International Inc. was named in a complaint for improperly marketing opioid drugs and revealed an internal probe into the medical supplier’s accounting, sending the company’s shares down.
A federal appeals court rejected a bid by eight drug retailers and distributors to disqualify the judge overseeing nationwide opioid litigation after they claimed his rulings, public statements and efforts to encourage settlements created an appearance of bias.
Eight drug companies urged a federal appeals court to disqualify the judge overseeing nationwide opioid litigation, in a last-ditch effort to avoid having him preside over a landmark trial.